{"id":"W3204767207","doi":"10.1016/j.annonc.2021.08.057","title":"661P Conditional survival and 5-year follow-up in CheckMate 214: First-line nivolumab + ipilimumab (N+I) versus sunitinib (S) in advanced renal cell carcinoma (aRCC)","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":false,"ca_institutions":"BC Cancer Agency","funders":"Bristol-Myers Squibb","keywords":"Medicine; Progression-free survival; Ipilimumab; Intention-to-treat analysis; Sunitinib; Internal medicine; Clinical endpoint; Randomized controlled trial; Surgery; Oncology; Overall survival; Renal cell carcinoma; Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007615925,0.0002531704,0.0008564378,0.0001876734,0.0002129393,0.0006547306,0.0002973265,0.0006435807,0.002245269],"category_scores_gemma":[0.001215763,0.0001351891,0.001302693,0.000180763,0.0002081076,0.000575984,0.0002882723,0.00118084,0.0002348575],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006876182,"about_ca_system_score_gemma":0.0006410308,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002057849,"about_ca_topic_score_gemma":0.003290609,"domain_scores_codex":[0.9997433,0.00005108156,0.0000150206,0.00008696212,0.00002342269,0.00008019246],"domain_scores_gemma":[0.9993606,0.000162641,0.0001448911,0.00004553058,0.00003010393,0.0002561602],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.604203,0.004309552,0.2402455,0.0004679146,0.003366011,0.000371869,0.0002251198,0.00532308,0.009205297,0.000334428,0.003637273,0.1283108],"study_design_scores_gemma":[0.01849745,0.1267657,0.8210326,0.0001783204,0.008229362,0.001197487,0.0003431914,0.01129681,0.006094667,0.0009841472,0.005262656,0.000117755],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9982464,0.0008648998,0.00004603137,0.00007600459,0.00003619178,0.000009593857,0.000323483,0.000008686799,0.0003887397],"genre_scores_gemma":[0.9987184,0.0002123236,0.00004557237,0.00006658191,0.00002110979,0.00001292691,0.000522594,0.000002731035,0.0003979264],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002245269,"threshold_uncertainty_score":0.007511199,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08853890813144567,"score_gpt":0.3488294023579169,"score_spread":0.2602904942264712,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}